B6.129P2-Cd44^tm1Mak/Cnbc

Status	Available to order
EMMA ID	EM:06743
Citation information	RRID:IMSR_EM:06743 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.
International strain name	B6.129P2-Cd44^tm1Mak/Cnbc
Alternative name	CD44
Strain type	Targeted Mutant Strains : Knock-out
Allele/Transgene symbol	Cd44^tm1Mak
Gene/Transgene symbol	Cd44

Information from provider

Provider	Tak W Mak
Provider affiliation	Mak Lab, Campbell Family Breast Cancer reseach Institute
Genetic information	Targeting vector replaces 3' end of exon 2 and the entire exon 3 with a neomycin resistance gene in an antisense orientation containing several stop codons for all reading frames.
Phenotypic information	Mice were born in Mendelian ratio without any obvious developmental or neurological deficits. Hematological impairment was evidenced by altered tissue distribution of myeloid progenitors with increased levels of colony-forming unit granulocyte-macrophage (CFU-GM) in bone marrow and reduced numbers of CFU-GM in spleen. Fetal liver colony-forming unit spleen and granulocyte colony-stimulating factor mobilization assays, together with reduced CFU-GM in peripheral blood, suggested that progenitor egress from bone marrow was defective.
Breeding history	Backcross into C57BL/6 10X.
References	CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity.;Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T, Wakeham A, Shahinian A, Catzavelos C, Rak J, Furlonger C, Zakarian A, Simard J J, Ohashi P S, Paige C J, Gutierrez-Ramos J C, Mak T W, ;1997;Blood;90;2217-33; 9310473 Absence of the CD44 gene prevents sarcoma metastasis.;Weber Georg F, Bronson Roderick T, Ilagan John, Cantor Harvey, Schmits Rudolf, Mak Tak W, ;2002;Cancer research;62;2281-6; 11956084
Homozygous fertile	yes
Homozygous viable	yes
Homozygous matings required	no
Immunocompromised	no

Information from EMMA

Archiving centre	CNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain
Animals used for archiving	homozygous C57BL/6J males

Disease and phenotype information

MGI phenotypes (allele matching)

abnormal leukocyte migration / MGI
impaired macrophage phagocytosis / MGI
liver inflammation / MGI
lung inflammation / MGI
decreased myocardial infarction size / MGI
enhanced coordination / MGI
increased mean systemic arterial blood pressure / MGI
impaired natural killer cell mediated cytotoxicity / MGI
increased circulating tumor necrosis factor level / MGI
increased circulating interferon-gamma level / MGI
increased circulating interleukin-2 level / MGI
decreased transforming growth factor level / MGI
decreased sensitivity to induced cell death / MGI
increased sensitivity to induced morbidity/mortality / MGI
abnormal circulating cytokine level / MGI
decreased activation-induced cell death of T cells / MGI
increased susceptibility to induced arthritis / MGI
abnormal vasculogenesis / MGI
delayed wound healing / MGI
peritoneal inflammation / MGI
decreased tumor growth/size / MGI
abnormal physiological neovascularization / MGI
abnormal vascular endothelial cell physiology / MGI
decreased susceptibility to kidney reperfusion injury / MGI
abnormal miniature excitatory postsynaptic currents / MGI
decreased acute inflammation / MGI
decreased circulating creatinine level / MGI
decreased blood urea nitrogen level / MGI
decreased angiogenesis / MGI
abnormal vascular endothelial cell morphology / MGI
decreased circulating tumor necrosis factor level / MGI
increased tumor necrosis factor secretion / MGI
abnormal interleukin secretion / MGI
increased interleukin-1 beta secretion / MGI
increased interleukin-10 secretion / MGI
increased interleukin-6 secretion / MGI
abnormal chemokine secretion / MGI
abnormal circulating chemokine level / MGI
abnormal cell morphology / MGI
abnormal definitive hematopoiesis / MGI
increased susceptibility to parasitic infection / MGI
immune system phenotype / MGI
abnormal vascular smooth muscle physiology / MGI
abnormal cell physiology / MGI
increased mitochondria size / MGI
abnormal mitochondrial crista morphology / MGI
decreased fibroblast proliferation / MGI

MGI phenotypes (gene matching)

decreased mast cell number / MGI
altered response to myocardial infarction / MGI
abnormal cell morphology / MGI
decreased mast cell histamine storage / MGI
abnormal uterus morphology / MGI
thin epidermis / MGI
abnormal lipid level / MGI
abnormal vasculogenesis / MGI
abnormal digestive system physiology / MGI
impaired wound healing / MGI
impaired macrophage phagocytosis / MGI
liver inflammation / MGI
lung inflammation / MGI
abnormal definitive hematopoiesis / MGI
no abnormal phenotype detected / MGI
abnormal CD4-positive, alpha beta T cell morphology / MGI
abnormal neutrophil physiology / MGI
short tibia / MGI
impaired skin barrier function / MGI
delayed wound healing / MGI
decreased myocardial infarction size / MGI
abnormal leukocyte migration / MGI
peritoneal inflammation / MGI
decreased susceptibility to induced arthritis / MGI
decreased tumor growth/size / MGI
abnormal leukocyte adhesion / MGI
abnormal physiological neovascularization / MGI
increased susceptibility to induced arthritis / MGI
enhanced coordination / MGI
decreased cholesterol level / MGI
abnormal vascular endothelial cell physiology / MGI
decreased susceptibility to kidney reperfusion injury / MGI
abnormal miniature excitatory postsynaptic currents / MGI
decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
increased mean systemic arterial blood pressure / MGI
abnormal CD8-positive, alpha beta T cell morphology / MGI
abnormal response to infection / MGI
increased susceptibility to parasitic infection / MGI
impaired natural killer cell mediated cytotoxicity / MGI
decreased acute inflammation / MGI
increased acute inflammation / MGI
decreased T cell proliferation / MGI
digestive/alimentary phenotype / MGI
immune system phenotype / MGI
hematopoietic system phenotype / MGI
abnormal CD4-positive, alpha-beta T cell physiology / MGI
abnormal T-helper 1 physiology / MGI
abnormal T-helper 2 physiology / MGI
choroidal neovascularization / MGI
decreased circulating creatinine level / MGI
decreased blood urea nitrogen level / MGI
abnormal vascular smooth muscle physiology / MGI
decreased angiogenesis / MGI
decreased susceptibility to type IV hypersensitivity reaction / MGI
abnormal cell physiology / MGI
abnormal vascular endothelial cell morphology / MGI
abnormal involution of the mammary gland / MGI
increased diameter of tibia / MGI
abnormal osteoclast differentiation / MGI
increased circulating tumor necrosis factor level / MGI
decreased circulating tumor necrosis factor level / MGI
increased tumor necrosis factor secretion / MGI
abnormal interleukin secretion / MGI
increased circulating interferon-gamma level / MGI
increased circulating interleukin-2 level / MGI
increased interleukin-1 beta secretion / MGI
increased interleukin-10 secretion / MGI
increased interleukin-6 secretion / MGI
impaired neutrophil recruitment / MGI
abnormal chemokine secretion / MGI
decreased transforming growth factor level / MGI
decreased sensitivity to induced cell death / MGI
abnormal epidermal lamellar body morphology / MGI
increased sensitivity to induced morbidity/mortality / MGI
abnormal circulating chemokine level / MGI
abnormal circulating cytokine level / MGI
decreased activation-induced cell death of T cells / MGI
increased mitochondria size / MGI
abnormal mitochondrial crista morphology / MGI
decreased fibroblast proliferation / MGI
impaired leukocyte tethering or rolling / MGI

Literature references

CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity.;Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T, Wakeham A, Shahinian A, Catzavelos C, Rak J, Furlonger C, Zakarian A, Simard J J, Ohashi P S, Paige C J, Gutierrez-Ramos J C, Mak T W, ;1997;Blood;90;2217-33; 9310473
Absence of the CD44 gene prevents sarcoma metastasis.;Weber Georg F, Bronson Roderick T, Ilagan John, Cantor Harvey, Schmits Rudolf, Mak Tak W, ;2002;Cancer research;62;2281-6; 11956084

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740^*
Rederivation of mice from frozen stock, delivery time available upon request . €3880^*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

^* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.

B6.129P2-Cd44tm1Mak/Cnbc